Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam
Issued Date
2024-10-01
Resource Type
ISSN
12019712
eISSN
18783511
Scopus ID
2-s2.0-85201784428
Pubmed ID
39094762
Journal Title
International Journal of Infectious Diseases
Volume
147
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Infectious Diseases Vol.147 (2024)
Suggested Citation
Thanh T.T., Tu N.T.K., Nguyet L.A., Thuy C.T., Thuan N.L.T., Ny N.T.H., Nhu L.N.T., Thanh L.K., Hong N.T.T., Anh N.T., Truong N.T., Chau N.V.V., Yen L.M., Van E P., Thuong N.P., Van Truc N., Trung P.H., Yap W.C., Pandey R., Yee S., Weng R., Mongkolsapaya J., Dejnirattisai W., Hamers R.L., Chantratita N., Screaton G., Dunachie S.J., Jones E.Y., Stuart D.I., Dung N.T., Thwaites G., Wang L.F., Tan C.W., Tan L.V. Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam. International Journal of Infectious Diseases Vol.147 (2024). doi:10.1016/j.ijid.2024.107173 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/100666
Title
Immunogenicity of Abdala COVID-19 vaccine in Vietnamese people after primary and booster vaccinations: A prospective observational study in Vietnam
Author(s)
Thanh T.T.
Tu N.T.K.
Nguyet L.A.
Thuy C.T.
Thuan N.L.T.
Ny N.T.H.
Nhu L.N.T.
Thanh L.K.
Hong N.T.T.
Anh N.T.
Truong N.T.
Chau N.V.V.
Yen L.M.
Van E P.
Thuong N.P.
Van Truc N.
Trung P.H.
Yap W.C.
Pandey R.
Yee S.
Weng R.
Mongkolsapaya J.
Dejnirattisai W.
Hamers R.L.
Chantratita N.
Screaton G.
Dunachie S.J.
Jones E.Y.
Stuart D.I.
Dung N.T.
Thwaites G.
Wang L.F.
Tan C.W.
Tan L.V.
Tu N.T.K.
Nguyet L.A.
Thuy C.T.
Thuan N.L.T.
Ny N.T.H.
Nhu L.N.T.
Thanh L.K.
Hong N.T.T.
Anh N.T.
Truong N.T.
Chau N.V.V.
Yen L.M.
Van E P.
Thuong N.P.
Van Truc N.
Trung P.H.
Yap W.C.
Pandey R.
Yee S.
Weng R.
Mongkolsapaya J.
Dejnirattisai W.
Hamers R.L.
Chantratita N.
Screaton G.
Dunachie S.J.
Jones E.Y.
Stuart D.I.
Dung N.T.
Thwaites G.
Wang L.F.
Tan C.W.
Tan L.V.
Author's Affiliation
Siriraj Hospital
Faculty of Tropical Medicine, Mahidol University
Oxford University Clinical Research Unit
Duke-NUS Medical School
Universitas Indonesia
NUS Yong Loo Lin School of Medicine
Agency for Science, Technology and Research, Singapore
University College London Hospitals NHS Foundation Trust
Nuffield Department of Medicine
Dong Thap University
Tan Phu District Hospital
Faculty of Tropical Medicine, Mahidol University
Oxford University Clinical Research Unit
Duke-NUS Medical School
Universitas Indonesia
NUS Yong Loo Lin School of Medicine
Agency for Science, Technology and Research, Singapore
University College London Hospitals NHS Foundation Trust
Nuffield Department of Medicine
Dong Thap University
Tan Phu District Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives: We studied the immunogenicity after primary and booster vaccinations of the Abdala COVID-19 vaccine, a receptor-binding domain protein subunit vaccine, in Vietnamese people by determining the level of neutralization and cross-neutralization activities against the ancestral SARS-CoV-2 and its variants and SARS-CoV-1. Methods: We performed a prospective observational study, enrolling adults aged 19-59 years in Dong Thap province, southern Vietnam, and collected blood samples from baseline until 4 weeks after the booster dose. We measured anti-nucleocapsid, anti-spike, and neutralizing antibodies against SARS-CoV-2 and assessed the cross-neutralization against 14 SARS-CoV-2 variants and SARS-CoV-1. Complementary antibody data came from Vietnamese health care workers fully vaccinated with ChAdOx1-S. Results: After primary vaccination, anti-spike antibody and neutralizing antibodies were detectable in 98.4% and 87% of 251 study participants, respectively, with neutralizing antibody titers similar to that induced by ChAdOx1-S vaccine. Antibody responses after a homologous (Abdala COVID-19) or heterologous (messenger RNA BNT162b2) booster could neutralize 14 SARS-CoV-2 variants (including Omicron) and SARS-CoV-1. Conclusions: Abdala COVID-19 vaccine is immunogenic in Vietnamese people. Enhanced antibody response after a booster dose could cross-neutralize 14 SARS-CoV-2 variants and SARS-CoV-1. Our results have added to the growing body of knowledge about the contribution of protein subunit vaccine platforms to pandemic control.